Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of Mosliciguat in PH-ILD
NCT06635850 · View on ClinicalTrials.gov ↗
Study Summary
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Conditions Studied
Interventions
- DRUG Placebo
- DEVICE Dry Powder Inhaler
- DRUG Mosliciguat
Study Locations (18)
California
- Ronald Reagan UCLA Medical Center — Los Angeles
- University of California Davis School of Medicine — Sacramento
- Harbor-UCLA Medical Center - Torrance — Torrance
North Carolina
- Duke University Health System - Duke Clinic — Durham
- PulmonIx — Greensboro
Arizona
- Arizona Pulmonary Specialists — Phoenix
Florida
- Florida Lung, Asthma & Sleep Specialists/Clinical Research Specialists, LLC — Celebration
Illinois
- Northwestern University — Chicago
Iowa
- University of Iowa Hospitals and Clinics — Iowa City
Kansas
- University of Kansas Medical Center — Kansas City
Kentucky
- Norton Pulmonary Specialists — Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2024-10-29 |
| Est. Completion | 2028-01 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06635850
The ClinicalTrials.gov registry entry for NCT06635850 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pulmovant, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 6 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 3 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06635850 reports 18 study locations spanning 15 distinct geographic areas — top geographies include California, North Carolina, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06635850 about?
NCT06635850 is a clinical study titled "A Study of Mosliciguat in PH-ILD". This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
What is the current status of trial NCT06635850?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2024-10-29. Estimated completion is 2028-01.
What conditions does trial NCT06635850 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Pulmonary Hypertension, Vascular Diseases, Interstitial Lung Disease, Lung Diseases. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06635850?
The interventions under investigation include: Placebo (DRUG), Dry Powder Inhaler (DEVICE), Mosliciguat (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06635850?
This trial is sponsored by Pulmovant, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06635850 being conducted?
This trial has 18 study locations across Arizona, California, Florida, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.